Melodi Health, a trailblazer in breast reconstruction technology, has achieved two significant milestones: the successful close of a $10.75 million Series A funding round and the commencement of the pivotal “ARIA” investigational device exemption (IDE) trial. The company’s efforts are centered on its groundbreaking device, the Melodi Matrix™, aimed at addressing post-surgical complications in breast cancer patients.
The Series A funding will bolster Melodi Health’s clinical activities and support further product development. With a total of $15 million raised since its inception in February 2021, the investment round saw participation from prominent investors including HM Venture Partners, Engage Venture Partners, Southeast Minnesota Capital Fund, and Three Bridges Private Capital.
Sarah Worrell, Co-founder and CEO of Melodi Health, expressed her enthusiasm: “We are delighted to reach these pivotal financial and clinical benchmarks. The Melodi Matrix represents a transformative approach to reducing post-surgical infections and enhancing patient outcomes. This innovative device fills a significant gap in current surgical options, aiming to mitigate complications that affect up to 14% of women undergoing mastectomy and reconstruction.”
Dr. Hunter Moyer, Chief Medical Officer at Melodi Health, added, “In reconstructive surgery, providing the best possible care involves utilizing the most advanced tools available. The Melodi Matrix offers both soft tissue support and infection prevention—essential elements that have been lacking in current options. This device represents a crucial advancement in our ability to improve patient outcomes.”
The “ARIA” trial, formally known as the Absorbable Antibacterial Soft Tissue Support in Breast Reconstruction with Infection Outcomes Assessment, is a multicenter, nationwide, randomized, controlled study. It aims to validate the safety and efficacy of the Melodi Matrix™, an absorbable mesh designed to support soft tissue while releasing antibiotic agents as it is absorbed. This device, utilizing proprietary technology licensed from Medtronic, is poised to address a significant need in breast reconstruction.
The trial’s first patient was enrolled at University of Utah Health. Dr. Alvin Kwok, Associate Professor of Surgery and Principal Investigator at the University of Utah, remarked, “A national infection rate of 10-14% in breast reconstruction procedures is unacceptable. I am eager to see how the Melodi Matrix impacts patient outcomes and helps reduce these infection rates.”
Editorial Perspective
Melodi Health’s recent achievements underscore the company’s pivotal role in advancing breast reconstruction technologies. With its innovative approach and substantial financial backing, Melodi Health is well-positioned to make a profound impact on the field of reconstructive surgery. The introduction of the Melodi Matrix™ could set new standards for infection prevention and tissue support, addressing a critical gap in current surgical options.
The strategic direction of Melodi Health, coupled with its robust clinical trials and strategic partnerships, reflects a strong commitment to improving patient outcomes and advancing medical technology. As the healthcare industry continues to evolve, Melodi Health’s focus on integrating cutting-edge technology with patient care promises to drive meaningful advancements in breast cancer treatment and reconstruction.
For further inquiries or feedback, please contact editor@thetimesmag.com.
